Related Experiment Videos
Choosing drug therapy for patients with hyperlipidemia
1Division of Family Practice, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
American Family Physician
|June 24, 2000
Summary
For millions of adults, diet and exercise fail to lower low-density lipoprotein (LDL) cholesterol. Statins are effective, well-tolerated drugs that significantly reduce LDL, coronary events, and mortality.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- 13 million American adults need drug therapy for low-density lipoprotein (LDL) goals.
- Diet and exercise are often insufficient for achieving lipid targets.
Purpose of the Study:
- To review the efficacy and tolerability of commonly prescribed lipid-lowering agents.
- To guide therapeutic choices for managing hyperlipidemia.
Main Methods:
- Literature review of major studies on lipid-lowering therapies.
- Analysis of drug classes including statins, niacin, fibrates, and bile acid sequestrants.
Main Results:
- Statins effectively reduce LDL, coronary events, and mortality; they are well-tolerated and widely prescribed.
- Niacin offers broad lipid benefits with improved tolerability in extended-release forms.
- Fibrates are primarily effective for lowering triglycerides.
- Bile acid sequestrants have limited use due to gastrointestinal side effects and administration issues.
Conclusions:
- Statins are the preferred first-line therapy for LDL reduction.
- Niacin and fibrates have specific roles in managing dyslipidemia.
- Drug selection should consider efficacy, side effect profile, and patient adherence.